Overlapping Method of Use Patents to Prevent Generic Entry

Area of Science:

• Pharmaceutical policy
• Intellectual property law
• Health economics

Background:

• Brand-name pharmaceutical firms utilize method of use patents and Orange Book use codes to extend market exclusivity.
• The "skinny labeling" pathway allows generic drugs to omit patented indications, facilitating market entry for unpatented uses.
• Overlapping use codes, targeting specific patient subgroups or biomarker thresholds, present a novel challenge to the skinny labeling pathway.

Purpose of the Study:

• To analyze how overlapping use codes obstruct the skinny labeling pathway.
• To examine the impact of these practices on generic drug entry, costs, and patient access.
• To propose reforms for FDA and USPTO oversight and legal standards.

Main Methods:

• Analysis of recent litigation concerning method of use patents and use codes.
• Case studies of icosapent ethyl (Vascepa) and sacubitril-valsartan (Entresto).
• Review of FDA and USPTO practices regarding use code assignments.

Main Results:

• Overlapping use codes effectively obstruct the skinny labeling pathway, delaying generic competition.
• Litigation involving Vascepa and Entresto demonstrates how these codes inflate costs and limit patient access to affordable alternatives.
• Current oversight and legal standards inadequately address the strategic use of overlapping codes to impede generic entry.

Conclusions:

• Reforms are necessary to enhance FDA and USPTO oversight of use code assignments.
• Clarifying legal standards for induced infringement is crucial.
• Preserving the balance between innovation incentives and timely access to affordable medicines requires addressing the misuse of use codes.